Tarsus Q2 XDEMVY Sales Surge 69% to $174M, Raises 2026 Guidance to $705M, Acquires Alkeus
TARS sits 44% above its 52-week low of $40.55 on light trading volume (0.4× avg).
Summary
Tarsus delivered a standout quarter with XDEMVY net sales of $173.9M, up 69% year-over-year, driven by volume and better gross-to-net. Full-year guidance was raised to $685-705M, signaling confidence in continued commercial momentum. The company also announced the acquisition of Alkeus Pharmaceuticals for up to $800 million, adding a Phase 3 program for Stargardt disease, and priced a $125M private placement to fund the deal. These moves follow the recent iRenix acquisition and CCO departure, showing aggressive pipeline expansion and commercial execution. The Alkeus deal and raised guidance materially shift the growth outlook, with multiple catalysts ahead including Phase 2 data for TP-04 and TP-05 in H1 2027.
Updates
· SEC 8-K — The 8-K details 2,098,519 shares at $56.00 and 133,625 pre-funded warrants at $55.9999, with closing expected August 7, 2026.
· SEC 8-K — The 8-K specifies $270M cash and $180M stock upfront, up to $350M in milestones, and low-to-mid single digit royalties on gildeuretinol sales.
At the time of this announcement, TARS was trading at $58.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $40.55 to $85.25. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.